{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:12626"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:12626","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Study of underlying mechanisms of NK cell impairment in B-CLL patients","abstract":"Despite the potent role of NK cells in eliminating the tumor and leukemic cells, NK cells in B-CLL patients are dysfunctional and impaired, which contributes to the disease progression and B-CLL patients’ mortality. NK cell impairment has been linked at least to the downregulation of activating receptors on NK cells in B-CLL patients. The first part of this study has investigated further the phenotype of NK cells and detailed functionality of NK cells from B-CLL patients. The data showed that the expression of checkpoint receptors on NK cells were significantly upregulated, including PD-1,CTLA-4, LAG-3 and CD96. Also, NK cells from B-CLL patients demonstrated reduced cytokine production and impaired DNAM-1 dependent NK cell cytotoxicity compared to age-matched healthy controls. In addition, TIGIT and/or CD96 blockades can robustly reverse the DNAM-1 dependent NK cytotoxicity against tumor cell lines. The second part of this study focused on PD-1positive NK cells. At first, scRNA-seq analysis revealed that PD-1pos NK cells have differentiated transcription profile compared to PD-1neg NK cells, which can be used to identify new potential therapeutic targets to reverse anti-tumor functions of PD-1pos NK cells. Secondly, the functionality of PD-1pos NK cells was compared with PD-1neg NK cells using primary NK cells and NK cell line models. The function of PD-1pos NK cells were significantly impaired compared to PD-1neg counterparts, including lower expression of cytokine and cytotoxicity against tumor cell lines. Interestingly, blocking of PD-1/PD-1Ls interactions have partially reversed the anti-tumor activity of PD-1pos NK cells. This study revealed for the first time that the checkpoint receptors expression on NK cells from B-CLL are upregulated and blocking PD-1 or TIGIT/CD96 receptors might be potential novel strategies for NK cell based immunotherapy for B-CLL patients.","abstract_html":"Despite the potent role of NK cells in eliminating the tumor and leukemic cells, NK cells in B-CLL patients are dysfunctional and impaired, which contributes to the disease progression and B-CLL patients’ mortality. NK cell impairment has been linked at least to the downregulation of activating receptors on NK cells in B-CLL patients. The first part of this study has investigated further the phenotype of NK cells and detailed functionality of NK cells from B-CLL patients. The data showed that the expression of checkpoint receptors on NK cells were significantly upregulated, including PD-1,CTLA-4, LAG-3 and CD96. Also, NK cells from B-CLL patients demonstrated reduced cytokine production and impaired DNAM-1 dependent NK cell cytotoxicity compared to age-matched healthy controls. In addition, TIGIT and/or CD96 blockades can robustly reverse the DNAM-1 dependent NK cytotoxicity against tumor cell lines. The second part of this study focused on PD-1positive NK cells. At first, scRNA-seq analysis revealed that PD-1pos NK cells have differentiated transcription profile compared to PD-1neg NK cells, which can be used to identify new potential therapeutic targets to reverse anti-tumor functions of PD-1pos NK cells. Secondly, the functionality of PD-1pos NK cells was compared with PD-1neg NK cells using primary NK cells and NK cell line models. The function of PD-1pos NK cells were significantly impaired compared to PD-1neg counterparts, including lower expression of cytokine and cytotoxicity against tumor cell lines. Interestingly, blocking of PD-1/PD-1Ls interactions have partially reversed the anti-tumor activity of PD-1pos NK cells. This study revealed for the first time that the checkpoint receptors expression on NK cells from B-CLL are upregulated and blocking PD-1 or TIGIT/CD96 receptors might be potential novel strategies for NK cell based immunotherapy for B-CLL patients.","abstract_has_math":false,"creators":["Farhat, Mustafa"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-07","date_published":"2022-07","updated_at":"2026-11-19T09:31:48Z","subjects":["QR180 Immunology"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/12626/7/Farhat2022PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A12626","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["other"]},{"key":"dc:creator","label":"Author","values":["Farhat, Mustafa"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2022-07-14"]},{"key":"dc:date.issued","label":"Date","values":["2022-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/12626/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QR180 Immunology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/12626/7/Farhat2022PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Despite the potent role of NK cells in eliminating the tumor and leukemic cells, NK cells in B-CLL patients are dysfunctional and impaired, which contributes to the disease progression and B-CLL patients’ mortality. NK cell impairment has been linked at least to the downregulation of activating receptors on NK cells in B-CLL patients. The first part of this study has investigated further the phenotype of NK cells and detailed functionality of NK cells from B-CLL patients. The data showed that the expression of checkpoint receptors on NK cells were significantly upregulated, including PD-1,CTLA-4, LAG-3 and CD96. Also, NK cells from B-CLL patients demonstrated reduced cytokine production and impaired DNAM-1 dependent NK cell cytotoxicity compared to age-matched healthy controls. In addition, TIGIT and/or CD96 blockades can robustly reverse the DNAM-1 dependent NK cytotoxicity against tumor cell lines. The second part of this study focused on PD-1positive NK cells. At first, scRNA-seq analysis revealed that PD-1pos NK cells have differentiated transcription profile compared to PD-1neg NK cells, which can be used to identify new potential therapeutic targets to reverse anti-tumor functions of PD-1pos NK cells. Secondly, the functionality of PD-1pos NK cells was compared with PD-1neg NK cells using primary NK cells and NK cell line models. The function of PD-1pos NK cells were significantly impaired compared to PD-1neg counterparts, including lower expression of cytokine and cytotoxicity against tumor cell lines. Interestingly, blocking of PD-1/PD-1Ls interactions have partially reversed the anti-tumor activity of PD-1pos NK cells. This study revealed for the first time that the checkpoint receptors expression on NK cells from B-CLL are upregulated and blocking PD-1 or TIGIT/CD96 receptors might be potential novel strategies for NK cell based immunotherapy for B-CLL patients."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Study of underlying mechanisms of NK cell impairment in B-CLL patients"]}]}],"canonical_facts":{"dc:contributor.sponsor":["other"],"dc:creator":["Farhat, Mustafa"],"dc:date":["2022-07-14"],"dc:date.issued":["2022-07"],"dc:description.abstract":["Despite the potent role of NK cells in eliminating the tumor and leukemic cells, NK cells in B-CLL patients are dysfunctional and impaired, which contributes to the disease progression and B-CLL patients’ mortality. NK cell impairment has been linked at least to the downregulation of activating receptors on NK cells in B-CLL patients. The first part of this study has investigated further the phenotype of NK cells and detailed functionality of NK cells from B-CLL patients. The data showed that the expression of checkpoint receptors on NK cells were significantly upregulated, including PD-1,CTLA-4, LAG-3 and CD96. Also, NK cells from B-CLL patients demonstrated reduced cytokine production and impaired DNAM-1 dependent NK cell cytotoxicity compared to age-matched healthy controls. In addition, TIGIT and/or CD96 blockades can robustly reverse the DNAM-1 dependent NK cytotoxicity against tumor cell lines. The second part of this study focused on PD-1positive NK cells. At first, scRNA-seq analysis revealed that PD-1pos NK cells have differentiated transcription profile compared to PD-1neg NK cells, which can be used to identify new potential therapeutic targets to reverse anti-tumor functions of PD-1pos NK cells. Secondly, the functionality of PD-1pos NK cells was compared with PD-1neg NK cells using primary NK cells and NK cell line models. The function of PD-1pos NK cells were significantly impaired compared to PD-1neg counterparts, including lower expression of cytokine and cytotoxicity against tumor cell lines. Interestingly, blocking of PD-1/PD-1Ls interactions have partially reversed the anti-tumor activity of PD-1pos NK cells. This study revealed for the first time that the checkpoint receptors expression on NK cells from B-CLL are upregulated and blocking PD-1 or TIGIT/CD96 receptors might be potential novel strategies for NK cell based immunotherapy for B-CLL patients."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/12626/7/Farhat2022PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/12626/"],"dc:subject":["QR180 Immunology"],"dcterms:accessrights":["public"],"dc:title":["Study of underlying mechanisms of NK cell impairment in B-CLL patients"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:31:48Z"}